United States: FDA Releases Long-Awaited Biological Naming Draft Guidance And Proposed Rule

On August 27, 2015, the U.S. Food and Drug Administration (FDA) released long-awaited and highly anticipated draft guidance regarding the non-proprietary naming of biological products, including biosimilars. The draft guidance was unexpectedly accompanied by a proposed rule in which FDA announced its intent to apply the proposed non-proprietary nomenclature scheme to six currently licensed biological products that are referenced by approved or publicly announced pending biosimilar applications, a product related to one of those reference products, or an approved biosimilar.

Key principles articulated in the draft guidance and/or proposed rule include:

  • FDA will assign biological products proper (i.e., non-proprietary) names that include (1) a core name and (2) a four lowercase-letter suffix attached to the core name with a hyphen. The proposed nomenclature scheme is intended to clearly identify biological products to improve pharmacovigilance, and, for the purposes of safe use, to clearly differentiate among biological products that have not been determined to be interchangeable.
    • For "originator" biological products, FDA intends to assign a core name that is the name adopted by the U.S. Adopted Names Council (USAN) for the drug substance (when available). An "originator" biological product is one that is the subject of a Biologics License Application (BLA) approved under Section 351(a) of the Public Health Service Act (i.e., as a "stand-alone  BLA") for which there is no previously licensed biological product licensed under a stand-alone BLA that is a "related" biological product.
    • For "related," biosimilar, or interchangeable biological products, FDA intends to assign a core name that is the name of the drug substance contained in the relevant previously licensed product. A "related" biological product is one that is licensed as a stand-alone BLA for which there is a previously licensed biological product submitted in a different stand-alone BLA that contains a drug substance for which certain nomenclature conventions (e.g., USAN would be expected to provide for use of the same drug substance name. The use of a shared core name is intended to indicate a relationship among the products.
    • For originator, related and biosimilar biological products, FDA intends to assign a unique suffix. For interchangeable products, FDA is considering whether the suffix should be distinct from or shared with the reference product. The FDA proposes that, in all cases, the suffix be four lowercase letters, unique and devoid of meaning. Moreover, the FDA notes that the suffix should not be promotional; include abbreviations commonly used in clinical practice; contain or suggest any drug substance name or core name designated by the USAN Council; look similar to or be mistaken for the name of a currently marketed product; or be too similar to any other product's suffix designation. The placement of the identifier as a suffix should result in biological products with the same core name being grouped together to help health care providers identify these products. If the naming convention is first applied to a new product, the request for FDA's review of the preferred suffix should occur during the investigational new drug (IND) phase or at the time of BLA submission. For BLA holders seeking to propose a distinguishing suffix after BLA approval, the FDA recommends that a prior-approval labeling supplemental application be submitted. An applicant should submit no more than three proposed suffixes, in the order of the applicant's preference. FDA will notify applicants of the suitability of the proposed suffix upon completion of the agency's evaluation. Once approved, the FDA expects that manufacturers will implement the new proper name at the time of their next manufacturing run and does not intend to object to manufacturers exhausting existing inventories of finished product not labeled with the new proper name.
  • The FDA intends to apply this naming convention to all biological products licensedincluding products previously licensedunder Section 351(a) or 351(k) of the Public Health Service Act. For previously licensed products, the revised proper name would generally be the product's original proper name plus the designated suffix. The FDA is considering the most effective regulatory approach to implement this naming convention for previously licensed products, but, in the near-term, intends to assign distinguishing suffixes to a limited group of products that are referenced by approved or publicly announced pending biosimilar applications (filgrastim, epoetin alfa, infliximab, pegfilgrastim), any related products to those reference products (tbo-filgrastim), or approved biosimilar product (filgrastim-sndz) through rulemaking. The proposed revised proper name for each product is summarized in the following table:

In the Federal Register notice that announced the availability of the draft guidance, the agency also posed several questions on which it specifically requests public comment (the following questions are reprinted from the Federal Register):

  • What are the potential benefits and challenges of designating a suffix in the proper name of a biological product that is:
    • Devoid of meaning versus meaningful (e.g., a suffix derived from the name of the license holder)
    • Unique to each biological product versus unique to each license holder and shared by each biological product manufactured by that license hold
      In your comments, please address how each option would impact the following: Safe use of biological products; pharmacovigilance; and market acceptance and uptake for certain products.
  • What would be the potential benefits and challenges for an interchangeable product to share the same suffix as designated in the proper name of the reference product? Your response should consider that FDA's publicly available electronic resource, the Purple Book, will identify biological products determined by FDA to be biosimilar to or interchangeable with a reference product. If an interchangeable product does share the same suffix as the reference product, how would this impact your responses to question 1, including pharmacovigilance?
  • Would there be additional benefits or challenges if the suffix designated in the proper name of a biosimilar product that is subsequently determined to be interchangeable were changed to that of the reference product upon a determination of interchangeability? Would there be benefits or challenges to allowing the manufacturer of the biosimilar product that is subsequently determined to be interchangeable to have the option of retaining its original suffix or adopting the same suffix as the reference product?
  • How could FDA and/or other Federal partners improve active pharmacovigilance systems for purposes of monitoring the safety of biological products? For example, because NDC numbers are not routinely recorded in billing and patient records in many clinical settings in which biological products are dispensed and administered, are there other identifiers besides distinguishable nonproprietary names that are routinely accessible by active pharmacovigilance systems and could enable as good as or better pharmacovigilance? How can FDA and/or other Federal partners help ensure that distinguishable identifier for each biological product would be captured at the point of dispensing or administration to the patient and be routinely accessible in systems used for pharmacovigilance?
  • What process and reasonable timeframe should FDA use to designate a suffix to include in the nonproprietary name of a previously licensed biological product?
  • What criteria should FDA use to prioritize retrospective application of this naming convention to previously licensed biological products?
  • What are the expected time frames for sponsors of previously licensed biological products to distribute products that conform to this naming convention after approval of a labeling supplement?
  • What strategies could FDA use to enhance stakeholders' understanding of and education about this naming convention?
  • FDA notes that this naming convention (i.e., use of a suffix) has some similarities to the World Health Organization (WHO) proposal, "Biological QualifierAn INN Proposal." At the time of publication of this draft guidance, WHO was still evaluating the comments received on its proposal. If WHO adopts a Biological Qualifier proposal, how should the biological qualifiers generated by WHO be considered in the determination of FDA designated proper names for the biological products within the scope of this guidance?

Interested stakeholders should submit comments regarding the draft guidance by October 27, 2015, and on the proposed rule by November 12, 2015.

Implications

Non-proprietary naming for biological—and, in particular, biosimilar—products has been a hot-button issue since Congress' created the biosimilar approval pathway in March 2010. Manufacturers for reference biological products have urged FDA to establish unique non-proprietary names for biosimilars, arguing that distinct names are required to facilitate pharmacovigilance and avoid prescriber confusion. Companies developing biosimilars, however, have argued that such concerns are overstated and that the request for distinct naming is primarily intended to serve as a barrier to market uptake of biosimilars.

When the FDA approved its first (and, to date, only) biosimilar earlier this year (Zarxio"), it assigned the product a non-proprietary name comprised of the reference product's non-proprietary name (filgrastim) and a suffix that identified the product's manufacturer. Although the agency explicitly stated that the name was a placeholder, and not necessarily indicative of its position with respect to biological naming in general, the assigned name suggested that the FDA believed the reference product manufacturers had the stronger of the two arguments. The draft guidance lends further support to this hypothesis, as the agency now proposes to add a unique suffix to the non-proprietary name for all originator, related and biosimilar biological products. The agency is presently unsure how to proceed with respect to biological products that are determined to be interchangeable with a reference product, however, and has specifically requested comments on this issue.  

Although reference product manufacturers will generally be pleased with the proposal for unique non-proprietary names, the draft guidance's proposal that the unique suffixes be "devoid of meaning" is likely to cause concern, as it is unclear that a non-memorable suffix would have the same uptake as a meaningful suffix (e.g., a suffix based on the manufacturer's name). The FDA has specifically requested comments on this issue as well, however, so interested parties still have ample opportunity to influence the agency's policy.

FDA Releases Long-Awaited Biological Naming Draft Guidance And Proposed Rule

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.